Skip to main content
. 2016 Jun 17;36(4):372–376. doi: 10.1097/JCP.0000000000000535

FIGURE 1.

FIGURE 1

Efficacy during the 25-week OL PP1M treatment phase.* A, Positive and Negative Syndrome Scale (PANSS).† B, Hamilton Rating Scale for Depression, 21-item version (HAM-D-21),† in subjects with baseline HAM-D-21 score ≥16. C, Young Mania Rating Scale (YMRS)† in subjects with baseline YMRS score ≥16. D, Proportion of subjects stabilized on paliperidone palmitate once-monthly injection.‡ CI, confidence interval; HAM-D-21, Hamilton Rating Scale for Depression, 21-item version; LOCF, last observation carried forward; PANSS, Positive and Negative Syndrome Scale; PP1M, paliperidone palmitate once-monthly. *P < 0.001 for change from baseline to end point. †Values are the mean (95% confidence interval). ‡PANSS score ≤70; YMRS and HAM-D-21 scores ≤12. The horizontal line in A–C indicates stabilization criteria.